Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

Rafael Nadal had been dealing with Müller-Weiss syndrome since he was 19 ...

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a ...

Alzheimer’s, Parkinson’s, Macular Degeneration, & MS Share a Common Thread. Groundbreaking Research May Halt Disease Progression for Thousands of Patients I have stabilized patients with these ...

MUMBAI, India & BASEL, Switzerland--(BUSINESS WIRE)--SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG today announced a collaboration to develop breakthrough small molecule ...

Treatment breakthroughs mean nothing for rare disease patients if they cannot access them. When you are living with the death ...

Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough ...

In his final months, First Descents leader Ryan O’Donoghue told nearly a dozen doctors he felt like he was suffering from dementia ...

Kubota Vision Inc. ("Kubota Vision"), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo ...

A local retinal surgeon and ophthalmology professor will speak about age-related macular degeneration during a free webinar ...

Three 2026 Breakthrough Prize winners reflect on developing Luxturna, a gene therapy that treats blindness caused by rare ...